332 related articles for article (PubMed ID: 28912358)
1. Combined oral contraceptives plus spironolactone compared with metformin in women with polycystic ovary syndrome: a one-year randomized clinical trial.
Alpañés M; Álvarez-Blasco F; Fernández-Durán E; Luque-Ramírez M; Escobar-Morreale HF
Eur J Endocrinol; 2017 Nov; 177(5):399-408. PubMed ID: 28912358
[TBL] [Abstract][Full Text] [Related]
2. Improved efficacy of low-dose spironolactone and metformin combination than either drug alone in the management of women with polycystic ovary syndrome (PCOS): a six-month, open-label randomized study.
Ganie MA; Khurana ML; Nisar S; Shah PA; Shah ZA; Kulshrestha B; Gupta N; Zargar MA; Wani TA; Mudasir S; Mir FA; Taing S
J Clin Endocrinol Metab; 2013 Sep; 98(9):3599-607. PubMed ID: 23846820
[TBL] [Abstract][Full Text] [Related]
3. Comparison of spironolactone and spironolactone plus metformin in the treatment of polycystic ovary syndrome.
Diri H; Karaburgu S; Acmaz B; Unluhizarci K; Tanriverdi F; Karaca Z; Kelestimur F
Gynecol Endocrinol; 2016; 32(1):42-5. PubMed ID: 26370923
[TBL] [Abstract][Full Text] [Related]
4. Metformin versus the combined oral contraceptive pill for hirsutism, acne, and menstrual pattern in polycystic ovary syndrome.
Fraison E; Kostova E; Moran LJ; Bilal S; Ee CC; Venetis C; Costello MF
Cochrane Database Syst Rev; 2020 Aug; 8(8):CD005552. PubMed ID: 32794179
[TBL] [Abstract][Full Text] [Related]
5. Comparative efficacy of statins, metformin, spironolactone and combined oral contraceptives in reducing testosterone levels in women with polycystic ovary syndrome: a network meta-analysis of randomized clinical trials.
Almalki HH; Alshibani TM; Alhifany AA; Almohammed OA
BMC Womens Health; 2020 Apr; 20(1):68. PubMed ID: 32248801
[TBL] [Abstract][Full Text] [Related]
6. In PCOS patients the addition of low-dose spironolactone induces a more marked reduction of clinical and biochemical hyperandrogenism than metformin alone.
Mazza A; Fruci B; Guzzi P; D'Orrico B; Malaguarnera R; Veltri P; Fava A; Belfiore A
Nutr Metab Cardiovasc Dis; 2014 Feb; 24(2):132-9. PubMed ID: 23845740
[TBL] [Abstract][Full Text] [Related]
7. The effect of combination therapy with metformin and combined oral contraceptives (COC) versus COC alone on insulin sensitivity, hyperandrogenaemia, SHBG and lipids in PCOS patients.
Cibula D; Fanta M; Vrbikova J; Stanicka S; Dvorakova K; Hill M; Skrha J; Zivny J; Skrenkova J
Hum Reprod; 2005 Jan; 20(1):180-4. PubMed ID: 15576394
[TBL] [Abstract][Full Text] [Related]
8. Association of oral contraceptive and metformin did not improve insulin resistance in women with polycystic ovary syndrome.
Iwata MC; Porquere L; Sorpreso IC; Baracat EC; Soares Júnior JM
Rev Assoc Med Bras (1992); 2015; 61(3):215-9. PubMed ID: 26248242
[TBL] [Abstract][Full Text] [Related]
9. Insulin-sensitising drugs versus the combined oral contraceptive pill for hirsutism, acne and risk of diabetes, cardiovascular disease, and endometrial cancer in polycystic ovary syndrome.
Costello M; Shrestha B; Eden J; Sjoblom P; Johnson N
Cochrane Database Syst Rev; 2007 Jan; (1):CD005552. PubMed ID: 17253562
[TBL] [Abstract][Full Text] [Related]
10. Oral contraceptive plus antiandrogen therapy and cardiometabolic risk in polycystic ovary syndrome.
Harmanci A; Cinar N; Bayraktar M; Yildiz BO
Clin Endocrinol (Oxf); 2013 Jan; 78(1):120-5. PubMed ID: 22702394
[TBL] [Abstract][Full Text] [Related]
11. Polycystic ovary syndrome and combined oral contraceptive use: a comparison of clinical practice in the United States to treatment guidelines.
Bird ST; Hartzema AG; Etminan M; Brophy JM; Delaney JA
Gynecol Endocrinol; 2013 Apr; 29(4):365-9. PubMed ID: 23311996
[TBL] [Abstract][Full Text] [Related]
12. Comparison of efficacy of spironolactone with metformin in the management of polycystic ovary syndrome: an open-labeled study.
Ganie MA; Khurana ML; Eunice M; Gupta N; Gulati M; Dwivedi SN; Ammini AC
J Clin Endocrinol Metab; 2004 Jun; 89(6):2756-62. PubMed ID: 15181054
[TBL] [Abstract][Full Text] [Related]
13. The effects of rosiglitazone and metformin on menstrual cyclicity and hirsutism in polycystic ovary syndrome.
Yilmaz M; Karakoç A; Törüner FB; Cakir N; Tiras B; Ayvaz G; Arslan M
Gynecol Endocrinol; 2005 Sep; 21(3):154-60. PubMed ID: 16335907
[TBL] [Abstract][Full Text] [Related]
14. Effect of metformin and spironolactone therapy on OGTT in patients with polycystic ovarian syndrome - a retrospective analysis.
Kulshreshtha B; Gupta N; Ganie MA; Ammini AC
Gynecol Endocrinol; 2012 Oct; 28(10):823-6. PubMed ID: 22475072
[TBL] [Abstract][Full Text] [Related]
15. Normalizing Ovulation Rate by Preferential Reduction of Hepato-Visceral Fat in Adolescent Girls With Polycystic Ovary Syndrome.
Ibáñez L; Del Río L; Díaz M; Sebastiani G; Pozo ÓJ; López-Bermejo A; de Zegher F
J Adolesc Health; 2017 Oct; 61(4):446-453. PubMed ID: 28712591
[TBL] [Abstract][Full Text] [Related]
16. Endothelial function and insulin resistance in polycystic ovary syndrome: the effects of medical therapy.
Teede HJ; Meyer C; Hutchison SK; Zoungas S; McGrath BP; Moran LJ
Fertil Steril; 2010 Jan; 93(1):184-91. PubMed ID: 19019358
[TBL] [Abstract][Full Text] [Related]
17. The impact of oral contraceptives and metformin on anti-Müllerian hormone serum levels in women with polycystic ovary syndrome and biochemical hyperandrogenemia.
Panidis D; Georgopoulos NA; Piouka A; Katsikis I; Saltamavros AD; Decavalas G; Diamanti-Kandarakis E
Gynecol Endocrinol; 2011 Aug; 27(8):587-92. PubMed ID: 20836726
[TBL] [Abstract][Full Text] [Related]
18. Comparison of ethinyl-estradiol plus cyproterone acetate versus metformin effects on classic metabolic cardiovascular risk factors in women with the polycystic ovary syndrome.
Luque-Ramírez M; Alvarez-Blasco F; Botella-Carretero JI; Martínez-Bermejo E; Lasunción MA; Escobar-Morreale HF
J Clin Endocrinol Metab; 2007 Jul; 92(7):2453-61. PubMed ID: 17426085
[TBL] [Abstract][Full Text] [Related]
19. Comparison of four different treatment regimes in hirsutism related to polycystic ovary syndrome.
Gökmen O; Senöz S; Gülekli B; Işik AZ
Gynecol Endocrinol; 1996 Aug; 10(4):249-55. PubMed ID: 8908525
[TBL] [Abstract][Full Text] [Related]
20. Polycystic ovary syndrome: a review for dermatologists: Part II. Treatment.
Buzney E; Sheu J; Buzney C; Reynolds RV
J Am Acad Dermatol; 2014 Nov; 71(5):859.e1-859.e15; quiz 873-4. PubMed ID: 25437978
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
